Search Results - "Nauroth, Julie"

Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer by Tsujikawa, Takahiro, Crocenzi, Todd, Durham, Jennifer N, Sugar, Elizabeth A, Wu, Annie A, Onners, Beth, Nauroth, Julie M, Anders, Robert A, Fertig, Elana J, Laheru, Daniel A, Reiss, Kim, Vonderheide, Robert H, Ko, Andrew H, Tempero, Margaret A, Fisher, George A, Considine, Michael, Danilova, Ludmila, Brockstedt, Dirk G, Coussens, Lisa M, Jaffee, Elizabeth M, Le, Dung T

“…Two studies in previously treated metastatic pancreatic cancer have been completed combining GVAX pancreas vaccine (GM-CSF-secreting allogeneic pancreatic…”
Get full text

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer by Yarchoan, Mark, Huang, Chiung‐Yu, Zhu, Qingfeng, Ferguson, Anna K., Durham, Jennifer N., Anders, Robert A., Thompson, Elizabeth D., Rozich, Noah S., Thomas, Dwayne L., Nauroth, Julie M., Rodriguez, Christina, Osipov, Arsen, De Jesus‐Acosta, Ana, Le, Dung T., Murphy, Adrian G., Laheru, Daniel, Donehower, Ross C., Jaffee, Elizabeth M., Zheng, Lei, Azad, Nilofer S.

“…Background Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor…”
Get full text

Biogenic Synthesis, Purification, and Chemical Characterization of Anti-inflammatory Resolvins Derived from Docosapentaenoic Acid (DPAn-6) by Dangi, Bindi, Obeng, Marcus, Nauroth, Julie M., Teymourlouei, Mah, Needham, Micah, Raman, Krishna, Arterburn, Linda M.

“…Enzymatically oxygenated derivatives of the ω-3 fatty acids cis-4,7,10,13,16,19-docosahexaenoic acid (DHA) and cis-5,8,11,14,17-eicosapentaenoic acid, known as…”
Get full text

Docosahexaenoic Acid (DHA) and Docosapentaenoic Acid (DPAn-6) Algal Oils Reduce Inflammatory Mediators in Human Peripheral Mononuclear Cells In Vitro and Paw Edema In Vivo by Nauroth, Julie M., Liu, Ying Chun, Van Elswyk, Mary, Bell, Rebecca, Hall, Eileen Bailey, Chung, Gloria, Arterburn, Linda M.

“…The anti-inflammatory activity associated with fish oil has been ascribed to the long-chain polyunsaturated fatty acids (LC-PUFA), predominantly…”
Get full text

A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint by Bever, Katherine M, Thomas, 2nd, Dwayne L, Zhang, Jiajia, Diaz Rivera, Ernie A, Rosner, Gary L, Zhu, Qingfeng, Nauroth, Julie M, Christmas, Brian, Thompson, Elizabeth D, Anders, Robert A, Judkins, Carol, Liu, Meizheng, Jaffee, Elizabeth M, Ahuja, Nita, Zheng, Lei, Azad, Nilofer S

“…Epigenetic therapies may modulate the tumor microenvironment. We evaluated the safety and optimal sequence of combination DNA methyltransferase inhibitor…”
Get full text

Docosahexaenoic acid reduces inflammation and joint destruction in mice with collagen-induced arthritis by Olson, Melissa V., Liu, Ying-Chun, Dangi, Bindi, Paul Zimmer, J., Salem, Norman, Nauroth, Julie M.

“…Objective This study was designed to determine the anti-inflammatory activity of docosahexaenoic acid (DHA), alone and in combination with eicosapentaenoic…”
Get full text

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial by Paller, Channing J., Zahurak, Marianna L., Mandl, Adel, Metri, Nicole A., Lalji, Aliya, Heath, Elisabeth, Kelly, William K., Hoimes, Christopher, Barata, Pedro, Taksey, Jason, Garrison, Dominique A., Patra, Kartick, Milne, Ginger L., Anders, Nicole M., Nauroth, Julie M., Durham, Jennifer N., Marshall, Catherine H., Markowski, Mark C., Eisenberger, Mario A., Antonarakis, Emmanuel S., Carducci, Michael A., Denmeade, Samuel R., Levine, Mark

“…High-dose intravenous vitamin C (HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but…”
Get full text

641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma by Baretti, Marina, Ladle, Brian, Nauroth, Julie, Wang, Hao, Durham, Jennifer, Thoburn, Christopher, Ferguson, Anna, Thompson, Alex, Brancati, Madalena, Griffith, Paige, Kamdar, Zeal, Kirk, Allison, Zaidi, Neeha, Huff, Amanda, Ho, Won, Furth, Mark, Thomas, Paul, Jaffee, Elizabeth M, Yarchoan, Mark

“…BackgroundFibrolamellar carcinoma (FLC) is a form of liver cancer primarily affecting children and young adults. The signature genomic event is a chimeric…”
Get full text

Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses by Jayaraman, Sahana, Montagne, Janelle M., Nirschl, Thomas R., Marcisak, Emily, Johnson, Jeanette, Huff, Amanda, Hsiao, Meng-Hsuan, Nauroth, Julie, Heumann, Thatcher, Zarif, Jelani C., Jaffee, Elizabeth M., Azad, Nilo, Fertig, Elana J., Zaidi, Neeha, Larman, H. Benjamin

“…Assays linking cellular phenotypes with T cell or B cell antigen receptor sequences are crucial for characterizing adaptive immune responses. Existing…”
Get full text

Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6) by Dangi, Bindi, Obeng, Marcus, Nauroth, Julie M., Chung, Gloria, Bailey-Hall, Eileen, Hallenbeck, Todd, Arterburn, Linda M.

“…17S-HDPAn-6 and 10S,17S-HDPAn-6 are resolvins produced from DPAn-6 by the action of lipoxygenase. Analysis of the metabolic stability and identification of…”
Get full text

Growth, clinical chemistry and immune function in domestic piglets fed varying ratios of arachidonic acid and DHA by TYBURCZY, Cynthia, KOTHAPALLI, Kumar S. D, WOO JUNG PARK, BLANK, Bryant S, LIU, Ying-Chun, NAUROTH, Julie M, PAUL ZIMMER, J, SALEM, Norman, THOMAS BRENNA, J

“…In the USA, infant formulas contain long-chain PUFA arachidonic acid (ARA) and DHA in a ratio of 2:1 and comprise roughly 0·66 g/100 g and 0·33 g/100 g total…”
Get full text

In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein by Fukumoto, Risaku, Andresen, Vibeke, Bialuk, Izabela, Cecchinato, Valentina, Walser, Jean-Claude, Valeri, Valerio W., Nauroth, Julie M., Gessain, Antoine, Nicot, Christophe, Franchini, Genoveffa

“…The human T-cell leukemia/lymphoma virus type 1 (HTLV-1) ORF-I encodes a 99–amino acid hydrophobic membrane protein, p12I, that affects receptors in different…”
Get full text

Memory lineage relationships in HTLV-1-specific CD8+ cytotoxic T cells by Johnson-Nauroth, Julie M., Graber, Jerome, Yao, Karen, Jacobson, Steve, Calabresi, Peter A.

“…Cytotoxic memory T cells play a critical role in combating viral infections; however, in some diseases they may contribute to tissue damage. In HAM/TSP, HTLV-1…”
Get full text

A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer by Haldar, Saurav Daniel, Heumann, Thatcher Ross, Berg, Maureen, Ferguson, Anna, Lim, Su Jin, Wang, Hao, Nauroth, Julie, Laheru, Dan, Jaffee, Elizabeth M., Azad, Nilofer Saba, Zaidi, Neeha

“…TPS814 Background: Novel strategies are needed to improve immune responses in “cold” tumors such as pancreatic ductal adenocarcinoma (PDAC) and mismatch…”
Get full text

Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy by Nakazawa, Mari, Kamdar, Zeal, Thomas, Amy, Durham, Jennifer N., Nauroth, Julie, Wang, Hao, Ladle, Brian H., Dykstra, Steven, Dugan, Margaret, Lafleur, Francois, Furth, Mark E., Leone, Robert D., Jaffee, Elizabeth M., Yarchoan, Mark, Baretti, Marina

“…TPS573 Background: Fibrolamellar carcinoma (FLC) is a rare, aggressive form of primary liver cancer predominantly affecting children and young adults under the…”
Get full text

A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer by Haldar, Saurav Daniel, Judkins, Carol, Ferguson, Anna, Abou Diwan, Elizabeth, Lim, Su Jin, Wang, Hao, Nauroth, Julie, Goggins, Michael, Laheru, Dan, Jaffee, Elizabeth M., Azad, Nilofer Saba, Zaidi, Neeha

“…TPS758 Background: KRAS mutations are identified in the majority of premalignant lesions that precede pancreatic ductal adenocarcinoma (PDAC). Arising during…”
Get full text

Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer by Paller, Channing Judith, Zahurak, Marianna, Heath, Elisabeth I., Kelly, William Kevin, Hoimes, Christopher J., Taksey, Jason David, Marshall, Catherine Handy, Markowski, Mark Christopher, Barata, Pedro C., Rudek, Michelle A., Nauroth, Julie, Wang, Lin, Durham, Jennifer N., Eisenberger, Mario A., Carducci, Michael Anthony, Denmeade, Samuel R., Levine, Mark

“…e17050 Background: Some phase I/II trials showed that combining high dose IV vitamin C with chemotherapies decreased toxicities and improved QoL in advanced…”
Get full text

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase 2 Trial by Paller, Channing J, Zahurak, Marianna L, Mandl, Adel, Metri, Nicole A, Lalji, Aliya, Heath, Elisabeth, Kelly, William K, Hoimes, Christopher, Barata, Pedro, Taksey, Jason, Garrison, Dominique A, Patra, Kartick, Milne, Ginger L, Anders, Nicole M, Nauroth, Julie M, Durham, Jennifer N, Marshall, Catherine H, Markowski, Mark C, Eisenberger, Mario A, Antonarakis, Emmanuel S, Carducci, Michael A, Denmeade, Samuel R, Levine, Mark

“…High-dose intravenous vitamin C(HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but…”
Get full text

Abstract CT036: Safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer: Preliminary analysis from a phase I study by Haldar, Saurav D., Huff, Amanda, Heumann, Thatcher R., Berg, Maureen, Ferguson, Anna, Lim, Su Jin, Wang, Hao, Thomas, Amy M., Nauroth, Julie M., Baretti, Marina, Bever, Katherine M., Yarchoan, Mark, Laheru, Daniel A., Jaffee, Elizabeth M., Azad, Nilofer S., Zaidi, Neeha

“…Background: Novel strategies are needed to decrease the high recurrence rates of pancreatic ductal adenocarcinoma (PDAC) after curative-intent surgery. Mutant…”
Get full text

Abstract CT022: Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study by Haldar, Saurav D., Huff, Amanda, Diwan, Elizabeth Abou, Ferguson, Anna, Judkins, Carol, Lu, Jiayun, Wang, Hao, Sinan, Hassan, Thoburn, Christopher, Bever, Katherine M., Yarchoan, Mark, Thomas, Amy M., Nauroth, Julie M., Laheru, Daniel A., Goggins, Michael G., Jaffee, Elizabeth M., Azad, Nilofer S., Zaidi, Neeha

“…Background: The development of pancreatic ductal adenocarcinoma (PDAC) from the first driver event takes >10 years, providing a unique window of opportunity…”
Get full text